Chinook Therapeutics U.S., Inc. was a biotechnology company with offices in Seattle, Washington, that focused on the discovery and development of precision medicines for kidney diseases.
Subscribe to see Chinook Therapeutics U.S., Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Chinook Therapeutics U.S., Inc. is a company headquartered in Seattle, United States. It has raised at least $180M across the 2 funding rounds on record. Its most recent funding round raised $115M in August 2020. Xcout tracks 26 named people at Chinook Therapeutics U.S., Inc., including Vasant (Vas) Narasimhan (Vasant (Vas) Narasimhan).
As of 17 November 2026. Source: Xcout Intel.
20 more named people on record for Chinook Therapeutics U.S., Inc., with roles, board committees and tenure — see the full roster →
At least $180M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $115M | — | |
| SEC Form D filing | $65M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Chinook Therapeutics U.S., Inc.'s closest competitors — see the full list of competitors and alternatives →
Goldfinch Bio, Inc. is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. The company focuses on discovering and developing precision medicines for the treatment of kidney diseases.
NephroDI Therapeutics, Inc. is a clinical-stage pharmaceutical and biotechnology company focused on developing specialized therapeutics. The company is headquartered in Seattle, Washington, United States.
Kanjin Therapeutics is a biotechnology startup headquartered in Wilmington, Delaware, with operations spanning the United States and Japan. Founded in 2025, the company focuses on pioneering medical interventions to restore kidney function and transform the treatment of chronic kidney diseases.
Walden Biosciences is a biotechnology company headquartered in Cambridge, Massachusetts, focused on developing first-in-class, highly targeted therapies for kidney diseases.
R1 Therapeutics is a renal-focused biotech company developing innovative, first-in-class, category-defining therapeutics for patients with kidney disease. Headquartered in San Francisco with additional offices in San Diego and Raleigh, the company started with lead asset AP306.
Kuleana Technology, Inc. is a Seattle-based startup founded in 2020 that is focused on improving renal replacement therapies. The company develops specialized medical technologies aimed at advancing treatments for kidney care.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Chinook Therapeutics U.S., Inc.? Suggest a correction · Work at Chinook Therapeutics U.S., Inc.? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.